文献速递认知障碍与痴呆

家族性阿尔茨海默病血清神经丝轻链:早期神经退行性变的标志物

Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.
PubMed 文献 · Neurology · 2017-10-25

本研究纳入48名来自PSEN1或APP突变家族的个体,采用Simoa平台检测血清NfL。结果显示,症状前和症状性突变携带者的血清NfL均高于非携带者,且与预估发病年数、认知及MRI指标相关。血清NfL可能是FAD早期神经退行性变的可行生物标志物。

要点

  • 症状前FAD突变携带者血清NfL已升高,提示早期神经退行性变。
  • 血清NfL与预估发病年数、认知评分及脑萎缩率显著相关。
  • 血清NfL或可作为FAD早期阶段的可行生物标志物。

核心结论

  • 血清NfL浓度在家族性阿尔茨海默病症状出现前即升高,并与疾病分期和严重程度指标相关。
  • 血清NfL可能是早期AD相关神经退行性变的可行生物标志物。

研究设计与样本

  • 横断面研究,招募48名来自PSEN1或APP突变家族的个体,其中18例为症状性AD,30例为无症状但50%风险携带突变。
  • 采用Simoa平台超敏免疫分析法检测血清NfL,并进行认知测试和MRI(33例有连续MRI以计算萎缩率)。
  • 通过基因检测确定突变状态,使用广义最小二乘回归模型比较各组血清NfL,并计算Spearman相关系数。

主要发现

  • 与无突变者相比,症状性突变携带者(p < 0.0001)和症状前突变携带者(p = 0.007)的血清NfL浓度均更高。
  • 在所有突变携带者中,血清NfL与EYO相关(ρ = 0.81,p < 0.0001)。
  • 血清NfL与MMSE(ρ = -0.62,p = 0.0001)、CDR-SB(ρ = 0.79,p < 0.0001)、基线脑体积(ρ = -0.62,p = 0.0002)及全脑萎缩率(ρ = 0.53,p = 0.01)相关。

临床怎么用

  • 在家族性AD症状前阶段可考虑检测血清NfL以评估早期神经退行性变。
  • 血清NfL水平可结合认知和MRI指标用于疾病分期和严重程度评估。

局限性

  • 横断面研究设计,样本量较小(48例),需纵向研究验证。
  • 仅纳入PSEN1或APP突变家族,结果外推至散发性AD需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether serum neurofilament light (NfL) concentration is increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and whether it is associated with markers of disease stage and severity. METHODS: We recruited 48 individuals from families with PSEN1 or APP mutations to a cross-sectional study: 18 had symptomatic Alzheimer disease (AD) and 30 were asymptomatic but at 50% risk of carrying a mutation. Serum NfL was measured using an ultrasensitive immunoassay on the single molecule array (Simoa) platform. Cognitive testing and MRI were performed; 33 participants had serial MRI, allowing calculation of atrophy rates. Genetic testing established mutation status. A generalized least squares regression model was used to compare serum NfL among symptomatic mutation carriers, presymptomatic carriers, and noncarriers, adjusting for age and sex. Spearman coefficients assessed associations between serum NfL and (1) estimated years to/from symptom onset (EYO), (2) cognitive measures, and (3) MRI measures of atrophy. RESULTS: Nineteen of the asymptomatic participants were mutation carriers (mean EYO -9.6); 11 were noncarriers. Compared with noncarriers, serum NfL concentration was higher in both symptomatic (p < 0.0001) and presymptomatic mutation carriers (p = 0.007). Across all mutation carriers, serum NfL correlated with EYO (ρ = 0.81, p < 0.0001) and multiple cognitive and imaging measures, including Mini-Mental State Examination (ρ = -0.62, p = 0.0001), Clinical Dementia Rating Scale sum of boxes (ρ = 0.79, p < 0.0001), baseline brain volume (ρ = -0.62, p = 0.0002), and whole-brain atrophy rate (ρ = 0.53, p = 0.01). CONCLUSIONS: Serum NfL concentration is increased in FAD prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017. PMID: 29070659. doi:10.1212/WNL.0000000000004667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。